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Abstract
Background: Pregnancy represents an exclusive situation in which the immune and the endocrine
system cooperate to prevent rejection of the embryo by the maternal immune system. While
immature dendritic cells (iDC) in the early pregnancy decidua presumably contribute to the
establishment of peripheral tolerance, glycoprotein-hormones of the transforming growth factor
beta (TGF-beta) family including activin A (ActA) and inhibin A (InA) are candidates that could
direct the differentiation of DCs into a tolerance-inducing phenotype.
Methods: To test this hypothesis we generated iDCs from peripheral-blood-monocytes and
exposed them to TGF-beta1, ActA, as well as InA and Dexamethasone (Dex) as controls.
Results:  Both glycoprotein-hormones prevented up-regulation of HLA-DR during cytokine-
induced DC maturation similar to Dex but did not influence the expression of CD 40, CD 83 and
CD 86. Visualization of the F-actin cytoskeleton confirmed that the DCs retained a partially
immature phenotype under these conditions. The T-cell stimulatory capacity of DCs was reduced
after ActA and InA exposure while the secretion of cytokines and chemokines was unaffected.
Conclusion: These findings suggest that ActA and InA interfere with selected aspects of DC
maturation and may thereby help preventing activation of allogenic T-cells by the embryo. Thus,
we have identified two novel members of the TGF-beta superfamily that could promote the
generation of tolerance-inducing DCs.
Background
Successful pregnancy depends on an adequate endocrine
response [1]. Apart from several steroid hormones such as
progesterone, estradiol and cortisol, also a number of
glycoprotein-hormones are secreted by the fetoplacental
unit in early human pregnancy [2]. Amongst those, two
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members of the transforming growth factor beta family
(TGF-β), namely activin A (ActA) and inhibin A (InA), are
present in the serum at dynamic levels during the first tri-
mester of human pregnancy [3]. Both hormones are
locally produced by the human placenta and fetal mem-
branes, which results in serum levels in the low ng/ml
range peaking at 10 weeks of gestation [4] ActA and InA
serve as useful diagnostic markers. ActA serum levels are
detectable in the sera of pregnant women starting at the
time when a pregnancy test is found to be positive. There-
fore, it has been speculated that ActA is an important
mediator of early embryonic as well as placental develop-
ment and decidualization [5]. Consequently, decreasing
ActA levels correlate both with an ongoing miscarriage
and ectopic pregnancy [6]. Increased InA levels allow pre-
diction of pregnancy following in vitro fertilization [7]
while decreasing InA levels are used as a specific marker to
reveal preclinical abortions [8,9].
In parallel with rising hormone levels, a significant
increase in leukocyte numbers is observed in the decidua
of early pregnancy. Amongst those, CD14+ monocytes are
a predominant cell population [10]. Following activation
by cytokines and growth factors, CD14+ monocytes can
differentiate into CD209+  immature dendritic cells
(iDCs), which are especially efficient in antigen uptake
and presentation. Exposure to maturation stimuli that
originate from infection or inflammation induces trans-
formation of iDCs into mature DCs (mDCs) that express
costimulatory molecules such as CD40, CD80, CD83 and
CD86 [11]. There is evidence that iDCs may contribute to
the establishment of peripheral tolerance in the absence
of such signals [12]. Additionally, it has been shown that
iDCs have the capacity to modulate regulatory T cells [13].
Both, in the non-pregnant human endometrium and the
decidua of early pregnancy, only a few CD83+ mDCs are
detected. In contrast, the number of iDCs is strongly
increased at this stage [14]. Therefore it has been sug-
gested that iDCs are important mediators of the immuno-
logical tolerance, which is indispensable for successful
pregnancy [15].
Up to now, several factors have been proposed which
could induce iDCs to adopt a tolerance-inducing pheno-
type and thereby prevent further maturation of these cells.
Amongst those are glucocorticoids, which are highly
potent modulators of the immune system. Indeed, several
studies have revealed that glucocorticoids are able to
impact the function of monocyte-derived DCs and to bias
them towards a tolerance-inducing phenotype [16,17].
Following exposure to Dexamethasone (Dex), a synthetic
glucocorticoid, DCs acquire the ability to convert the local
cytokine pattern to support TH2 responses [18,19]. Dex-
treated DCs are resistant to maturation induced by
lipopolysaccharide (LPS) or CD40 ligand and produce
high amounts of interleukin 10 (IL-10) [20]. TGF-β1,
another factor known to exert immunosuppressive effects,
was found to inhibit the maturation of DCs and to con-
comitantly induce the generation of tolerogenic DCs
[21,22]. Moreover, exposure of TGF-β1-pretreated cells to
maturation stimuli prevented up-regulation of CD86 and
CD83, classical features of mature DCs [23]. Since ActA
and InA are members of the TGF-β family, we speculated
that these glycoprotein-hormones might also exert immu-
nosuppressive functions and thereby inhibit the matura-
tion of iDCs in the human pregnancy decidua. Thus, we
examined the influence of ActA and InA on the matura-
tion and function of DCs. Our studies revealed that both
hormones exert potent effects on at least some features of
DCs that partially resemble those seen after Dex or TGF-
β1 treatment. Thus, glycoprotein-hormones such as ActA
and InA are likely candidates to contribute to the periph-
eral tolerance seen in the human pregnancy decidua.
Methods
Dendritic cell preparation
Buffy coats were obtained from healthy male and female
human donors (University of Würzburg, Department of
Immunohematology and Transfusion Medicine, Ger-
many). Cells were isolated and cultured as described by
Romani et al. [24]. After dilution with an equal volume of
phosphate buffered saline (PBS), citrate buffered buffy
coats were distributed over a density-gradient (density
1.077 g/ml, leukocyte separation medium, PAA, Cölbe,
Germany) and centrifuged at 400 g for 30 min at room
temperature. Peripheral blood mononuclear cells (PBMC)
were collected from the interface and washed with PBS,
resuspended in AIMV-Medium (Gibco, Invitrogen, Karl-
sruhe, Germany) and incubated for 1 h at 37°C with gen-
tamycine (20 µg/ml; Biochrom, Berlin, Germany) and 2%
autologous plasma on plastic dishes (TPP, Trasadigen,
Switzerland). To remove non-adherent cells, the dishes
were thoroughly washed several times with PBS. The
remaining adherent cell fraction was used for the genera-
tion of monocyte-derived DCs by culturing them with 800
U/ml purified recombinant human granulocyte macro-
phage colony-stimulating factor (GM-CSF; Leukomax,
Brussels, Belgium) and 250 U/ml IL-4 (Immuno-Tools,
Friesoythe, Germany) for 5 days in RPMI 1640 (Bio-
chrom) with 10% fetal calf serum (FCS: PAN, Aidenbach,
Germany) and 20 µg/ml gentamycine. On day 3 half of
the volume of medium was replaced by fresh medium and
IL-4/GM-CSF.
Maturation of DCs was induced on day 4 by adding an
inflammatory cocktail containing 1000 U/ml purified
recombinant human IL-1β, 1000 U/ml purified recom-
binant human IL-6, 1000 U/ml purified recombinant
human tumor necrosis factor alpha (TNFα) (all Immu-
notools, Friesoythe, Germany) and 10-8 mol/l prostaglan-Reproductive Biology and Endocrinology 2008, 6:17 http://www.rbej.com/content/6/1/17
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din E2 (PGE2; Calbiochem, Bad Soden, Germany) for 24
hours resulting in mDCs. To obtain iDCs for control, an
aliquot of the cells remained in culture for another 24
hours in IL-4/GM-CSF medium without addition of the
maturation cocktail. All cells were harvested on day 5 for
further experiments.
Hormonal treatment of DC cultures
ActA, InA, TGF-β1 or Dex were added at the following
concentrations to the cultured cells on day 4 in parallel
with the maturation-inducing cytokines: 100 ng/ml ActA,
100 ng/ml InA, 4 ng/ml TGF-β1 and 10-6 M Dex. All hor-
mones were used in water-soluble form. TGF-β1 was
obtained from Biozol (Eching, Germany), ActA from
tebu-bio (Offenbach, Germany), InA from diagnostic sys-
tems laboratories (Webster, UK) and Dex from Sigma-
Aldrich (Deisenhofen, Germany).
For analysis, the cells were harvested after 24 h of culture.
FACS Analysis
Flow cytometry of DCs was performed using FITC-labeled
specific antibodies and the respective isotype controls:
CD40 (clone: 5C3, Pharmigen, Heidelberg, Germany),
CD83 (clone: HB 15a; Beckman/Coulter, Krefeld, Ger-
many) and CD86 (clone: FUN-1, Pharmigen), HLA-DR
(clone: AB3, Dako, Hamburg, Germany). Briefly, samples
of 2×5 × 105 cells were resuspended in 50 µl PBS supple-
mented with 10% human immunoglobulin (Beriglobi-
lin®, Centeon, Marburg, Germany). 5 µl of the antibodies
were added to the cell suspension and incubated for 30
minutes at 4°C (1:10 dilution). The cells were washed,
resuspended in 100 µl PBS and analyzed in a FACScan
flow cytometer (BD Biosciences, Heidelberg, Germany).
Propidium iodide (at 10 ng/ml) was used to identify non-
viable cells. A total of 10.000 viable cells per sample were
evaluated for specific staining. Results were analyzed
using the WinMDI-software (Version 2.8, Joseph Trotter
Scripps University, USA).
Confocal microscopy
8-well-chamber LabTekII slides (Nunc, Wiesbaden, Ger-
many) were coated with 0.01% Poly-L-Lysin (Sigma-
Aldrich, Taufkirchen, Germany) for 5 min at 37°C and
subsequently washed with PBS. DCs were resuspended in
culture medium and attached to precoated slides for 20
min at 37°C at a density of 4 × 105 cells in 100 µl. Cells
were fixed with 4% paraformaldehyde for 10 min at RT,
permeabilized with Triton X-100 for 5 min, washed with
PBS and blocked with 5% BSA/PBS for 20 min. F-actin
was stained using Alexa488-fluorochrom conjugated
Phalloidin (Molecular Probes, Karlsruhe, Germany) for
20 min in 1% BSA/PBS. After washing with PBS the slides
were dried and mounted with Fluoromount-G medium
(Southern Biotech, Biozol, Eching, Germany). Imaging
was performed using Zeiss LSM 410 Meta confocal micro-
scope, equipped with 63× oil objective (NA 1.4) and laser
line 488 for excitation. For each analysis 100–200 DCs
were randomly counted.
Cytokine bead array (CBA)
Production of multiple cytokines by cultured DCs was
simultanously determined using a CBA kit (BD Bio-
sciences, Heidelberg, Germany). To this end, 50 µl of cul-
ture supernatant was incubated with a set of beads that
have been coated with cytokine specific antibodies, which
serves as a capture surface for cytokines. Each supernatant
was analyzed in undiluted form as well as after diluting
1:10 and 1:100 in "Assay diluent" included in the CBA kit.
Beads specific for IL-8, IL-10, IL-12, monocyte chemoat-
tractant protein-1 (MCP-1) and for regulated on activa-
tion normal T-cell expressed and secreted (RANTES) were
detected in a FACSCanto II flow cytometer (BD Bio-
sciences) and the total amount of cytokines was then
determined based on fluorescence intensity using the
FCAP Array 1.0 software (Soft Flow).
Mixed lymphocyte reaction (MLR)
T-cells were isolated from PBMCs by incubating them for
1 hour at 4°C with neuraminidase (Boehringer Ingel-
heim, Ingelheim, Germany) treated sheep red blood cells.
Rosettes consisting of T cells were collected following a
density gradient (see DC preparation) and prepared with
0.8% NH4Cl for lysis. Subsequently, remaining T cells
were washed in PBS and resuspended in RPMI. The purity
of the T cell preparations was assessed by flow cytometric
analysis of CD3, CD4 and CD8 and routinely found to be
around 98%. In order to achieve strong enough prolifera-
tion to allow measurement by a non-radioactive method,
T cells were prepared following the "oxidative mitogene-
sis" protocols as published by Hill et al. 1999 [25]. In
brief, purified T cells were incubated in 0,5 mM sodium
periodide for 15 min on ice, washed in FCS followed by
two washings in RPMI1640/10%FCS. To test the capacity
of DCs to stimulate allogenic T cells, the DCs were cocul-
tured in graded doses of 9000 to 111 cells per well with 9
× 104  allogenic sodium-periodide-treated T-cells for 3
days in U-bottom 96-well plates in a volume of 350 µl in
RPMI1640/10%FCS/gentamycin. To determine the prolif-
eration-index, the cultures were incubated with WST-8 cell
proliferation array kit (Biozol, Eching, Germany) in a
modified MTT assay for 2 hours. Optical density was ana-
lyzed at 450 nm using a microplate reader. 6–8 independ-
ent assays were performed for each condition.
Data analysis
In total, 8–14 independent experiments were analyzed for
each test system. Since the PBMC donors did not conform
to a normal distribution pattern as assessed by the Sha-
piro-Wilkins test for normality, we used the WicoxonReproductive Biology and Endocrinology 2008, 6:17 http://www.rbej.com/content/6/1/17
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Signed Rank test for statistical analysis of relative changes
in cytokine concentration, and the nonparametric Mann
Whitney U test for the comparison of surface marker
expression, podosome formation and lymphocyte stimu-
latory capacity under the influence of the hormones. Sta-
tistical analyses refer to comparisons between hormonal
treatments and the corresponding mDC sample. P-values
< 0.05 were considered as significant (Graph-Pad Soft-
ware, San Diego, USA).
Results
Since the samples had been anonymized, the gender of
the blood sample donors from which the DCs were
derived was initially determined by PCR (AMXP gene
analysis) according to Mitchell et al. [26]. Since no differ-
ences were observed between male (n = 6) and female (n
= 8) donors the samples were combined. However, broad
individual variations were observed in all parameters ana-
lyzed during the course of this study that were not related
to the gender of the blood sample donors.
Dex but not ActA and InA inhibit the expression of typical 
surface markers of mature DC
Firstly, we determined whether pretreatment with preg-
nancy-associated glycoprotein- hormones affected the
phenotype of DCs during maturation. To this end, iDCs
were stimulated with an inflammatory cocktail in the
presence of the selected hormones and analyzed by flow
cytometry for surface expression of molecules that charac-
terize the differentiation stage of DCs. As known previ-
ously, iDCs express low levels of CD40, CD83, CD86 as
well as HLA-DR. While CD40 and HLA-DR were only
slightly upregulated during the maturation process, CD83
and CD86 became considerably induced on mature DCs,
which was significantly prevented by Dex (Figure 1). In
contrast, there was no clear effect on cell surface expres-
sion observed for any of the three glycoprotein hormones
(Figure 1).
Treatment with ActA and InA impacts on the F-actin 
cytoskeleton of DCs
Since maturation of DCs is accompanied by dramatic
changes in the cytoskeletal organization and morphology
[27,28], we investigated the influence of hormonal treat-
ment on F-actin remodeling by Phalloidin staining and
confocal microscopy (Figure 2). The phenotype of iDCs
was characterized by strongly enlarged cell bodies, podo-
somes and cell-substratum contact zones on the cell
edges. In contrast, mDCs were round-shaped and dis-
played a complete loss of podosomal stuctures. Addition
of Dex to iDC cultures during maturation fully prevented
the adoption of a mature phenotype. This can be con-
cluded from the morphological inspection of the cells and
was confirmed by quantification of podosome-carrying
cells (Figure 2A, B). Treatment with TGF-β1, ActA or InA
also interfered with the maturation process by preveting F-
Actin remodeling and inhibiting the dissolution of podo-
somes. However, the effects of the glycoprotein-hormones
were less pronounced as compared to those of Dex (Figure
2).
Cytokine and chemokine secretion are unaffected by ActA 
and InA
A major hallmark of mDCs is their spectrum of secreted
mediators such as cytokine and chemokines that differs
from the one of iDCs. Maturation of DCs by incubation
with the inflammatory cocktail strongly increased the
secretion of IL-8, MCP-1 and RANTES (Figure 3). In con-
trast, IL-10 levels did not change. Maturation in the pres-
ence of Dex significantly prevented up-regulation of IL-8
and RANTES secretion. Furthermore, IL-10 concentrations
in the cell culture supernatant significantly increased in
Dex treated cells. A strong impact of Dex on MCP-1 secre-
tion was observed in all samples, however did not reach
significance due to the large standard deviation. Neither
incubation with TGFβ 1, ActA nor InA had any significant
impact on the production of any of the mediators, even
though we observed a non-significant down-regulation of
MCP-1 secretion by TGF-β1, ActA and InA (Figure 3).
Thus, none of the glycoprotein-hormones affects the
release of the cytokines and chemokines tested herein fol-
lowing DC maturation.
ActA and InA interfere with the T-cell stimulatory capacity 
of DCs
Mixed lymphocyte reaction (MLR) experiments allow
assessing the ability of DCs to serve as potent antigen pre-
senting cells (APCs) during T-cell priming. As expected,
the T-cell stimulatory capacity of iDCs was very low in
comparison to that observed for mDCs. DCs matured in
the presence of Dex were clearly impaired in their ability
to induce T cell proliferation (Figure 4a). Similarly, TGF-
β1, ActA and InA pre-treatment also resulted in a dimin-
ished T-cell stimulatory capacity of DCs, an effect that was
comparable to the one of Dex (Figure 4a). At a DC:T ratio
of 1:10, the capacity of matured DCs to induce allogeneic
T cell stimulation was significantly reduced by all four
hormones (Figure 4b). Thus, the pregnancy-associated
glycoprotein-hormones not only interfere with the phe-
notype and morphology of DCs but also impair the func-
tion of DCs and their ability to serve as APCs during T-cell
priming.
Discussion
ActA and InA are known to play a key role in implantation
and early embryo development [2-9]. Furthermore, ActA
is also involved in inflammatory responses [29] and
works as a chemoattractant for monocytes [30,31]. Recent
studies revealed that ActA is able to modulate immune
responses via type I and II activin receptors on DCs [32].Reproductive Biology and Endocrinology 2008, 6:17 http://www.rbej.com/content/6/1/17
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Impact of ActA and InA on the maturation of DCs Figure 1
Impact of ActA and InA on the maturation of DCs. Immature dendritic cells (iDCs) were generated from PBMCs of 
healthy donors by culturing with IL-4 and GM-CSF. Differentiation into mature DCs (mDCs) was achieved by addition of an 
inflammatory cytokine cocktail for 24 hours. To study the impact of various hormones on the maturation process, maturation 
was performed in the presence or absence of Dex, TGF-β1, ActA or InA. Subsequently, the cells were analyzed for surface 
expression of CD40, CD83, CD86 and HLA-DR by flow cytometry. Representative histograms (left panel) are depicted for 
each hormonal treatment (grey shaded areas); analysis of corresponding iDCs (grey line) and mDCs (black line) are shown in 
each histogram for control. In addition, statistical analysis of the mean fluorescence intensity (MFI) as a quantitative measure 
for surface expression levels is depicted as bar diagrams (right panel). n = 14.
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Influence of ActA and InA on the F-actin cytoskeleton of DCs Figure 2
Influence of ActA and InA on the F-actin cytoskeleton of DCs. iDCs generated from PBMCs of healthy donors were 
differentiated into mDCs in the presence or absence of Dex, TGF-β1, ActA and InA. Changes in cell morphology were 
assessed by confocal microscopy following staining with Phalloidin-Alexa488 to visualize F-Actin structures. (A) Representative 
pictures of iDCs, mDCs and DCs matured in the presence of one of the four hormones are depicted; bar: 20 µm. (B) Quanti-
fication of the number of podosome-forming cells for each experimental condition as a measure of the degree of DC matura-
tion. For each analysis 100–200 DCs were randomly counted. Mean +/- SEM; n = 5; ** p < 0.01, * p < 0.05 (hormonal 
treatment vs. mDC).
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In early human pregnancy, a considerable recruitment of
iDCs can be detected in human decidua compared to non-
pregnant endometrium [14]. So far, it remains elusive
whether ActA and InA exert immunomodulatory effects
on the phenotype and function of DCs. Therefore we
examined whether those two glycoprotein-hormones
influence the maturation of DCs.
Since the inhibitory effect of Dex on the phenotype and
function of DCs is well established [16-20], this was used
as an internal control in all experiments. The doses of
TGF-β1, ActA and InA used in the cell culture experiments
were selected based previous publications [5,18,23]. In
accordance with earlier studies [16,17] Dex treated DCs
retained an apparently immature phenotype (CD40low,
CD83low, CD86low, HLA-DRlow). However, there was no
clear effect of the three glycoprotein hormones on any of
the four surface markers. This observation is in contrast to
previous findings, which described a down-regulation of
CD 40 and the costimulatory molecule CD86 by TGF-β1
in murine DC [23]. Proper functioning as antigen-pre-
senting cells (APCs) requires DCs to change their mor-
Cytokine and chemokine secretion in the presence of ActA and InA Figure 3
Cytokine and chemokine secretion in the presence of ActA and InA. The culture supernatant of iDCs induced to dif-
ferentiate into mDCs in the presence or absence of the four hormones was analyzed by cytokine bead array for the production 
of IL-8, IL-10, MCP-1 and RANTES. Mean +/- SEM, n = 7- 8; ** p < 0,01 (hormonal treatment vs. mDC).
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T-cell stimulatory activity of DCs matured in the presence of ActA and InA Figure 4
T-cell stimulatory activity of DCs matured in the presence of ActA and InA. (A) DC function was analyzed in a 
mixed lymphocyte reaction (MLR) by incubating DCs obtained under different culture conditions with T lymphocytes at the 
indicated ratios. T-cell proliferation induced by iDCs, mDCs or DCs matured in the presence of Dex, TGF-β1, ActA or InA 
was measured on the basis of the measured optical density as described in the methods section. Mean +/- SEM; n = 8. (B) At a 
DC:T ratio of 1:10, the reduction of the T-cell stimulatory capacity of the DCs was significantly reduced by all four hormones. 
Each bar represents n = 8 independent experiments.
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phology during the maturation process [28]. While iDCs
are large cells with extensive lamellopodia and numerous
podosomes, mDCs are much smaller and discontinue to
exhibit those structures. Findings by others [33,34] and us
demonstrate that glucocorticoids almost fully prevent the
morphological alterations occurring during maturation
and thereby interfere with the ability of DCs to serve as
potent APCs. Here we showed that in the presence of the
glycoprotein-hormones TGF-β1, ActA and InA, DCs also
retained a partially immature phenotype although the
effects were less strong in comparison to Dex. This sug-
gests that TGF-β1, ActA and InA are able to modulate the
maturation of DCs in terms of morphology.
The decidual micromilieu comprises a mixture of pro- and
anti-inflammatory factors. It is believed that during preg-
nancy, pro-inflammatory factors support placentation by
a self-destruction process of the decidual stroma [35,36]
whilst anti-inflammatory cytokines rather induce a toler-
ant phenotype of DCs. ActA plays a complex role in vari-
ous inflammatory processes. Since ActA is rapidly released
into the circulation after intravenous injection of LPS
[29], it likely represents a critical component of the early
inflammatory pathway [37]. In line with this notion, ActA
acts on key modulators of the inflammatory process such
as TNF-α, IL-1β and IL-6 [29]. Furthermore, IL-6 and IL-8
production in amnion explants were found to be signifi-
cantly stimulated by ActA [38] while it was inhibited at
elevated levels of ActA [38]. In our system, neither TGF-
β1, ActA nor InA significantly altered the production of
pro- and anti-inflammatory chemokines and cytokines.
As suggested by other groups, we therefore assume that
ActA and InA rather work as genuine cytokines [37] and
have only little impact on the direct modulation of medi-
ator production by DCs. The suitability of our assay was
confirmed by the finding that Dex strongly inhibited the
production of the pro-inflammatory cytokine IL-8 and
RANTES [29] as well as increased IL-10 synthesis [39].
Dex as the protagonist of an immunomodulatory hor-
mone strongly interfered with surface expression, mor-
phology and mediator production by DCs. In contrast, the
three glycoprotein-hormones TGF-β1, ActA and InA
exerted some but not all effects of Dex and also not to the
same magnitude. Nevertheless, functional analysis of the
T-cell stimulatory capacity of DCs matured in the presence
of the four pregnancy-associated hormones clearly
showed that all of them interfered with this important
characteristic. TGF-β1, ActA and InA clearly reduced T-cell
proliferation compared to mDCs. These findings are con-
sistent with a recent report demonstrating that ActA atten-
uates the T-cell stimulatory capacity as measured by the
expansion of antigen-specific CD8+ T cells [32].
A general observation of all our experiments was that the
effects of hormonal pre-treatment on DC maturation dif-
fered between individual donors. While some DC prepa-
rations showed very strong effects, others responded
quantitatively weaker despite using standardized proce-
dures. Since an impact of the gender of the donors could
be excluded, we hypothesize that individual difference in
the capacity of DCs to respond to maturation stimuli may
exist. The effects of pre-incubation with TGF-β1, ActA, InA
or Dex were most conspicuous when DCs were matured
with the hormones for 24 hours. In contrast, addition to
the cell cultures during differentiation of the monocytes
into iDCs resulted in a deformation or even apoptosis of
a large proportion of the cells (data not shown).
It is a well-known fact that the levels of ActA and InA in
early pregnancy correlate with the success or failure of
pregnancy but the underlying processes remain elusive.
Our results now provide for the first time a rationale that
these hormones are able to exert immunomodulatory
functions that are important for the acceptance of the fetal
semiallograft by supporting the development of toler-
ance-inducing DCs.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SES drafted the manuscript, set up the experiments, partic-
ipated in data collection, analysed and interpreted the
results. NM carried out the confocal microscopy, analysed
the results and provided images and figures. JB carried out
the cytokine bead arrays, MK cultivated the cells and car-
ried out the FACS analysis, JD participated in editorial
support, HMR participated in design of the study, pro-
vided images and figures and revised the article for intel-
lectual content. LR participated in the study design,
experimental concept, and data interpretation UK partici-
pated in the study design, analysis and interpretation of
the results and drafting of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by grants of the DFG (Klinische Forschergruppe 
124/2-3 to UK and HMR.) and RE1631/1-3 (to HMR.).
References
1. Soldin OP, Guo T, Weiderpass E, Tractenberg RE, Hilakivi-Clarke L,
Soldin SJ: Steroid hormone levels in pregnancy and 1 year
postpartum using isotope dilution tandem mass spectrome-
try.  Fertil Steril 2005, 84:701-710.
2. Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S: Inhibin
A and activin A in the first trimester of human pregnancy.  J
Clin Endocrinol Metab 1997, 82:1557-1560.
3. Muttukrishna S, Jauniaux E, McGarrigle H, Groome N, Rodeck CH:
In-vivo concentrations of inhibins, activin A and follistatin in
human early pregnancy.  Reprod Biomed Online 2004, 8:712-719.
4. Lockwood GM, Ledger WL, Barlow DH, Groome NP, Muttukrishna
S: Measurement of inhibin and activin in early human preg-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2008, 6:17 http://www.rbej.com/content/6/1/17
Page 10 of 10
(page number not for citation purposes)
nancy: demonstration of fetoplacental origin and role in pre-
diction of early-pregnancy outcome.  Biol Reprod 1997,
57(6):1490-1494.
5. Jones RL, Salamonsen LA, Findlay JK: Potential roles for endome-
trial inhibins, activins and follistatin during human embryo
implantation and early pregnancy.  Trends Endocrinol Metab
2002, 13:144-150.
6. Florio P, Severi FM, Bocchi C, Luisi S, Mazzini M, Danero S, Torricelli
M, Petraglia F: Single serum activin a testing to predict ectopic
pregnancy.  J Clin Endocrinol Metab 2007, 92:1748-1753.
7. Hauzman E, Fedorcsak P, Klinga K, Papp Z, Rabe T, Strowitzki T,
Urbancsek J: Use of serum inhibin A and human chorionic
gonadotropin measurements to predict the outcome of in
vitro fertilization pregnancies.  Fertil Steril 2004, 81:66-72.
8. Muttukrishna S, Jauniaux E, Greenwold N, McGarrigle H, Jivraj S,
Carter S, Elgaddal S, Groome N, Regan L: Circulating levels of
inhibin A, activin A and follistatin in missed and recurrent
miscarriages.  Hum Reprod 2002, 17:3072-3078.
9. Prakash A, Laird S, Tuckerman E, Li TC, Ledger WL: Inhibin A and
activin A may be used to predict pregnancy outcome in
women with recurrent miscarriage.  Fertil Steril 2005,
83:1758-1763.
10. Kammerer U, Eggert AO, Kapp M, McLellan AD, Geijtenbeek TB,
Dietl J, van Kooyk Y, Kampgen E: Unique appearance of prolifer-
ating antigen-presenting cells expressing DC-SIGN (CD209)
in the decidua of early human pregnancy.  Am J Pathol 2003,
162:887-896.
11. Moretta A: Natural killer cells and dendritic cells: rendezvous
in abused tissues.  Nat Rev Immunol 2002, 2:957-964.
12. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic den-
dritic cells.  Annu Rev Immunol 2003, 21:685-711.
13. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Stein-
man RM: Efficient targeting of protein antigen to the dendritic
cell receptor DEC-205 in the steady state leads to antigen
presentation on major histocompatibility complex class I
products and peripheral CD8+ T cell tolerance.  J Exp Med
2002, 196:1627-1638.
14. Rieger L, Honig A, Sutterlin M, Kapp M, Dietl J, Ruck P, Kammerer U:
Antigen-presenting cells in human endometrium during the
menstrual cycle compared to early pregnancy.  J Soc Gynecol
Investig 2004, 11:488-493.
15. Dietl J, Honig A, Kammerer U, Rieger L: Natural Killer Cells and
Dendritic Cells at the Human Feto-maternal Interface: an
Effective Cooperation?  Placenta 2005, 27(4–5):341-347.
16. Matasic R, Dietz AB, Vuk-Pavlovic S: Dexamethasone inhibits
dendritic cell maturation by redirecting differentiation of a
subset of cells.  J Leukoc Biol 1999, 66:909-914.
17. de Jong EC, Vieira PL, Kalinski P, Kapsenberg ML: Corticosteroids
DC and induce the development of tolerogenic DC.  J Leukoc
Biol 1999, 66:201-204.
18. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, Socci
C, Di CV: Glucocorticoids affect human dendritic cell differ-
entiation and maturation.  J Immunol 1999, 162:6473-6481.
19. Elenkov IJ: Glucocorticoids and the Th1/Th2 balance.  Ann N Y
Acad Sci 2004, 1024:138-146.
20. Xia CQ, Peng R, Beato F, Clare-Salzler MJ: Dexamethasone
induces IL-10-producing monocyte-derived dendritic cells
with durable immaturity.  Scand J Immunol 2005, 62:45-54.
21. Li G, Abediankenari S, Kim YJ, Campbell TB, Ito S, Graham-Evans B,
Cooper S, Broxmeyer HE: TGF-{beta}1 combined with M-CSF
and IL-4 induces generation of immune inhibitory cord blood
dendritic cells capable of enhancing cytokine-induced ex-
vivo expansion of myeloid progenitors.  Blood 2007,
110(8):2872-2879.
22. Strobl H, Knapp W: TGF-beta1 regulation of dendritic cells.
Microbes Infect 1999, 1:1283-1290.
23. Mou HB, Lin MF, Cen H, Yu J, Meng XJ: TGF-beta1 treated
murine dendritic cells are maturation resistant and down-
regulate Toll-like receptor 4 expression.  J Zhejiang Univ Sci
2004, 5:1239-1244.
24. Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, Nieder-
wieser D, Schuler G: Generation of mature dendritic cells from
human blood. An improved method with special regard to
clinical applicability.  J Immunol Methods 1996, 196(2):137-151.
25. Hill ME, Ferguson DJ, Austyn JM, Newsom-Davis J, Willcox HN:
Potent immunostimulatory dendritic cells can be cultured in
bulk from progenitors in normal infant and adult myasthenic
human thymus.  Immunology 1999, 97(2):325-332.
26. Mitchell RJ, Kreskas M, Baxter E, Buffalino L, Van Oorschot RA: An
investigation of sequence deletions of amelogenin (AMELY),
a Y-chromosome locus commonly used for gender determi-
nation.  Ann Hum Biol 2006, 33(2):227-240.
27. Ross R, Jonuleit H, Bros M, Ross XL, Yamashiro S, Matsumura F, Enk
AH, Knop J, Reske-Kunz AB: Expression of the actin-bundling
protein fascin in cultured human dendritic cells correlates
with dendritic morphology and cell differentiation.  J Invest
Dermatol 2000, 115(4):658-663.
28. Schuurhuis DH, Fu N, Ossendorp F, Melief CJ: Ins and outs of den-
dritic cells.  Int Arch Allergy Immunol 2006, 140(1):53-72.
29. Jones KL, de Kretser DM, Clarke IJ, Scheerlinck JP, Phillips DJ: Char-
acterisation of the rapid release of activin A following acute
lipopolysaccharide challenge in the ewe.  J Endocrinol 2004,
182(1):69-80.
30. Erämaa M, Hurme M, Stenman UH, Ritvos O: Activin A/erythroid
differentiation factor is induced during human monocyte
activation.  J Exp Med 1992, 176(5):1449-1452.
31. Shao L, Frigon NL Jr, Sehy DW, Yu AL, Lofgren J, Schwall R, Yu J: Reg-
ulation of production of activin A in human marrow stromal
cells and monocytes.  Exp Hematol 1992, 20(10):1235-1242.
32. Robson NC, Phillips DJ, McAlpine T, Shin A, Svobodova S, Toy T, Pil-
lay V, Kirkpatrick N, Zanker D, Wilson K, Helling I, Wei H, Chen W,
Cebon J, Maraskovsky E: Activin-A: a novel dendritic cell
derived cytokine which potently attenuates CD40 ligand-
specific cytokine and chemokine production.  Blood 2007,
111(5):2733-2743.
33. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, van
Kooten C: The effect of calcineurin inhibitors and corticoster-
oids on the differentiation of human dendritic cells.  Eur J
Immunol 2000, 30(7):1807-1812.
34. Mainali ES, Tew JG: Dexamethasone selectively inhibits differ-
entiation of cord blood stem cell derived-dendritic cell (DC)
precursors into immature DCs.  Cell Immunol 2004, 232(1–
2):127-136.
35. Apte RN, Voronov E: Interleukin-1-a major pleiotropic
cytokine in tumor-host interactions.  Semin Cancer Biol 2002,
12:277-290.
36. Bischof P, Meisser A, Campana A: Mechanisms of endometrial
control of trophoblast invasion.  J Reprod Fertil Suppl 2000,
55:65-71.
37. Phillips DJ, Jones KL, Clarke IJ, Scheerlinck JP, de Kretser DM:
Activin A: from sometime reproductive factor to genuine
cytokine.  Vet Immunol Immunopathol 2005, 108(1–2):23-27.
38. Keelan JA, Zhou RL, Evans LW, Groome NP, Mitchell MD: Regula-
tion of activin A, inhibin A, and follistatin production in
human amnion and choriodecidual explants by inflamma-
tory mediators.  J Soc Gynecol Investig 2000, 7(5):291-296.
39. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP: Modulatory
effects of glucocorticoids and catecholamines on human
interleukin-12 and interleukin-10 production: clinical impli-
cations.  Proc Assoc Am Physicians 1996, 108(5):374-81.